Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.
NCT06498037
Summary
The primary objective is to evaluate the effect of loading boluses when dose incresaing treatment with SC fentanyl in patients with cancer. The primary endpoint of this study is to prove the non-inferiority of fentanyl plasma concentrations 12 hours after dose augmentation compared to 48 hours after dose augmentation within each patient. Patients will be treated with additional loading boluses and plasma-PK samples will be obtained.
Eligibility
Inclusion Criteria: * Age ≥18 years; * Able to understand the written information and able to give informed consent. * Current or planned treatment with SC fentanyl for cancer-related pain Exclusion Criteria: * Pregnancy or/ and breastfeeding * Other ways of using fentanyl (sublingual, nasal spray and oromucosal) * Liver function CPS B or C * The use of strong CYP3A4 inhibitors of inducers \[9\] * Presence of somnolence, respiratory depression or CTCAE grade 2 adverse events.
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06498037